Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Ist Teil von
The New England journal of medicine, 2011-02, Vol.364 (5), p.422-431
Ort / Verlag
Waltham, MA: Massachusetts Medical Society
Erscheinungsjahr
2011
Quelle
Electronic Journals Library
Beschreibungen/Notizen
In this randomized trial of fidaxomicin as compared with vancomycin in 629 patients, oral fidaxomicin was shown to be noninferior to oral vancomycin in the treatment of
C. difficile
infection and was associated with lower rates of recurrence.
Clostridium difficile
infection generally occurs after exposure to broad-spectrum antibiotics. The incidence and severity of
C. difficile
infection are increasing. The increases have been ascribed to the emergence of a hypervirulent
C. difficile
strain, known variously as North American Pulsed Field type 1 (NAP1), restriction-endonuclease analysis (REA) type BI, or polymerase-chain-reaction ribotype 027 (referred to collectively as the NAP1/BI/027 strain).
1
–
4
Furthermore, the rates of death associated with
C. difficile
infection are rising,
5
–
7
and the infection is occurring in populations that were previously considered to be at low risk, such as young, healthy persons living in the community and . . .